Daniel Hübschmann

Oct 2, 2023 | nature.com | Peter-Martin Bruch |Tobias Roider |Claudia D. Baldus |Hubert Serve |Daniel Hübschmann |Carsten Müller-Tidow | +3 more

AbstractEx vivo drug response profiling is a powerful tool to study genotype–drug response associations and is being explored as a tool set for precision medicine in cancer. Here we conducted a prospective non-interventional trial to investigate feasibility of ex vivo drug response profiling for treatment guidance in hematologic malignancies (SMARTrial, NCT03488641). The primary endpoint to provide drug response profiling reports within 7 d was met in 91% of all study participants (N = 80).